Detection of extended-spectrum β-lactamase enzymes (ESBLs) produced by Escherichia coli urinary pathogens at Assiut University Hospital

Bulletin of Pharmaceutical Sciences

Volumn 34, Issue PART 2, 2011, Pages 93-103

  Thabit, Amany G ^a   El Khamissy, Tharwat R ^b   Ibrahim, Maggie A ^a   Attia, Adel E ^b  

^a Assiut University Faculty of Medicine   (Egypt)

^b Cairo University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFOPERAZONE; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CANDIDA; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISK DIFFUSION; ESCHERICHIA COLI; GENE SEQUENCE; GENOTYPE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; UNIVERSITY HOSPITAL; URINALYSIS; URINARY TRACT INFECTION;

EID: 84862902424     PISSN: 11100052     EISSN: None     Source Type: Journal    
DOI: 10.21608/bfsa.2011.63247     Document Type: Article

References (49)

1. A. Ronald, "The etiology of urinary tract infection traditional and emerging pathogens", Am. J. Med., 113 (supp l1A), 14S-19S (Level III) (2002).
2. W. E. Stamm and S. R. Norrby, "Urinary tract infections: disease panorama and challenges", J. Infect. Dis., 183, pp. s1-s4 (2001).
3. M. D. Bethesda, "National kidney and urologic diseases information clearing house", NIH Publication, No. 08, 3925 (2005).
4. D. C. Bean, K. Daniel and W. W. David, "Antimicrobial resistance in community and nosocomial E. coli urinary tract isolates, London 2005-2006", Annals of Clin. Microbiol. Antimicrob., 25, 7-13 (2008).
5. T. Hooton, "The current management strategies for community-acquired urinary tract infection", Infect. Dis. Clin. North. Am., 17, 303-332 (2003).
6. A. A. Kader and K. Angamuthu, "Extended-spectrum β-lactamases in urinary isolates of E. coli, K. pneumoniae and other Gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia", Saudi Med. J., 26 (6), 956-959 (2005).
7. A. Valverde, T. M. Coque, Garcia- M. L. San, F. Baquero and R. Canton, "Complex molecular epidemiology of extended-spectrum β-lactamases in K. pneumoniae: a long-term perspective from a single institution in Madrid", J. Antimicrob. Chemother., 61, 64-72 (2008).
8. J. D. Pitout, M. D. Reisbig and E. C. Venter, "Modification of the double-disc test for detection of Enterobacteriaceae producing extended-spectrum and AmpC β-lactamases", J. Clin. Microbiol., 41 (8), 3933-3935 (2003).
9. M. J. Schwaber, P. M. Raney and J. K. Rasheed, "Utility of NCCLS guidelines for identifying extended-spectrum β-lactamases in non-E. coli and non-Klebsiella spp. of Enterobacteriaceae", ibid., 42 (1), 294-298 (2004).
10. S. M. Drawz and R. A. Bonomo, "Three decades of β-lactamase inhibitors", Clin. Microbiol. Rev., 3 (1), 160-201 (2010).
11. C. H. Lee, L. H. Su, Y. F. Tang and J. W. Liu, "Treatment of ESBL-producing K. pneumoniae bacteraemia with carbapenems or flomoxef: A retrospective study and laboratory analysis of the isolates", J. Antimicrob. Chemother., 58 (5), 1074-1077 (2006).
12. A. D. Harris, J. C. McGregor, J. A. Johnson, S. M. Strauss, A. C. Moore, H. C. Standiford, J. N. Hebden and J. G. Jr. Morris, "Risk factors for colonization with extended-spectrum β-lactamase-producing bacteria and intensive care unit admission", Emerg. Infect. Dis., 13 (8), 1144-1149 (2007).
13. E. T. Lautenbach, J. B. Patel, W. B. Bilker, P. H. Edelstein and N. O. Fishman, "Extended-spectrum β-lactamase-Producing E. coli and K. pneumoniae: Risk factors for infection and impact of resistance on outcomes", Clin. Infect. Dis., 32, 1162-1171 (2001).
14. K. S. Thomson, "Controversies about extended-spectrum and AmpC β-lactamases", Emerg. Infect. Dis., 7 (2), 333-336 (2001).
15. D. L. Paterson, "Resistance in Gramnegative bacteria: Enterobacteriaceae", Am. J. Med., 119 (6SUPPL. 1), S20-S28 (2006).
16. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, Issued October. Am. J. I. C., 32 (8), 470-485 (2004).
17. D. L. Paterson, W. C. Ko and A. Von Gottberg, "Antibiotic therapy for K. pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases", Clin. Infect. Dis., 39, 31-7 (2004).
18. th Informational Supplement M100-S17. Vol. 27, Clinical and Laboratory Standards Institute, Wayne, PA. (2007).
19. G. B. Schumann and F. N. Greenberg, "Usefulness of macroscopic urine analysis as a screening procedure", Am. J. Clin. Pathol., 71, 452-6 (1979).
20. P. D. Hoeprich, "Culture of the urine", J. Lab. Clin. Med., 56, 899-907 (1960).
21. st ELBS ed. Cambridge, UK, 1989, pp. 248-263.
22. M. Cheesbrough, "District Laboratory Practice in Tropical Countries", Cambridge University Press, UK, Part II, 2006, p. 63.
23. th ed. Philadelphia: JB Lippincott Co., 1997, pp. 171-230.
24. th Informational Supplement M100-S17., Vol. 27. Clinical and Laboratory Standards Institute, Wayne, PA. (2005).
25. V. Jarlier, M. H. Nicolas, G. Fournier and A. Philippon, "Extended-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae hospital prevalence and susceptibility patterns", Rev. Infect. Dis., 10, 867-878. (1988).
26. P. D. Lister, V. M. Gardner and C. C. Sanders, "Clavulanate induces expression of the Ps. aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin", Antimicrob. Agents Chemother., 43, 882-889 (1999).
27. M. G. Cormican, S. A. Marshall and R. N. Jones, "Detection of extended-spectrum β-lactamase (ESBLs)-producing strains by the ESBL- E-Test screen", J. Clin. Microbiol., 34 (8), 1880-1884 (1996).
28. J. Kim, J. Semi, R. Hogeun, L. Bokkwon, P. Misun, L. Hoanjong, M. D. Jina and K. Seonghan, "Rapid detection of extended-spectrum β-lactamase (ESBL) for Enterobacteriaceae by use of a multiplex PCR-based method", Infect. Chemother., 41 (3), 181-184 (2009).
29. E. Stürenburg, A. Kuhn, D. Mack and R. Laufs, "A novel extended-spectrum β-lactamase CTX-M-23 with a P167T substitution in the active site omega loop associated with ceftazidime resistance", J. Antimicrob. Chemother., 54, 406-409 (2004).
30. N. H. Ryoo, E. C. Kim, S. G. Hong, Y. J. Park, K. Lee, I. K. Bae, E. H. Song and S. H. Jeong, "Dissemination of SHV-12 and CTX-M-type extended-spectrum β-lactamases among clinical isolates of E. coli and K. pneumoniae and emergence of GES-3 in Korea", ibid., 56, 698-702 (2005).
31. A. R. Ronald, L. E. Nicolle, E. Stamm, J. Krieger, J. Warren and A. Shaeffer, "Urinary tract infection in adults: research priorities and strategies", Int. J. Antimicrob. Agents, 17, 343-8 (2001).
32. A. A. Oladipo, A. Abdul-Rasheed, W. Babatunde Odetoyin, and L. Adebayo, "Antimicrobial resistance in E. coli strains from urinary tract infections", J. Nat. Med. Assoc., 101, 1268-1273 (2009).
33. M. Tirthankar, K. Pramod, S. Gita and Y. R. Medha, "Nosocomial infections in geriatric patients admitted in ICU", J. I. A. G., 2, 61-64 (2005).
34. G. G. Zhanel, T. L. Hisanaga, N. M. Laing, M. R. DeCorby, K. A. Nichol, B. Weshnoweski, J. Johnson, A. Noreddin D. E. Low, J. A. Karlowsky; for the NAUTICA Group and D. J. Hoban, "Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)", Int. J. Antimicrob. Agents, 26, 380-388 (2005).
35. M. T. Taher and G. Ali, "Symptomatic nosocomial urinary tract infection in ICU patients: identification of antimicrobial resistance pattern", IJCID, 4 (1), 25-29 (2009).
36. A. Mirsalehian, F. Akbari-Nakhjavani, A. Peymani, B. Kazemi, F. J. Ameli and S. M. Mirafshar, "Prevalence of extended-spectrumß-lactamase- producing enterobacteriaceae by phenotypic and genotypic methods in intensive care units in Tehran, Iran", DARU, 16, (3), 169-173 (2008).
37. S. H. Ahmed, E. A. Daef, M. S. Badary, M. A. Mahmoud and A. A. Abd-Elsayed, "Nosocomial blood stream infection in intensive care units at Assiut University Hospitals (Upper Egypt) with special reference to extended-spectrum β-lactamase producing organisms", BMC Research Notes, 2 (76), 1-11 (2009).
38. P. Agrawal, A. Ghosh and S. Kumar, "Prevalence of extended-spectrum β-lactamases among E. coli and K. pneumoniae isolates in a tertiary care hospital", Indian J. Pathol. Microbiol., 51 (1), 139-142 (2008).
39. S. E. Mshana, "State of the globe: Evaluating the existence of extended-spectrum β-lactamases", J. Global Infect. Dis., 1 (2), 85-86 (2009).
40. P. A. Bradford, C. Urban, N. Mariano, S. J. Projan, J. J. Rahal and K. Bush,"Imipenem resistance in K. pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase and the loss of an outer membraneprotein", Antimicrob. Agents Chemother., 41, 563-569 (1997).
41. K. S. Thomson, C. C. Sanders and E. S. Moland, "Use of microdilution panels with and without β-lactamase inhibitors as a phenotypic test for β-lactamase production among E. coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii and Serratia marcescens", ibid., 43, 1393-1400 (1999).
42. C. Mabilat and P. Courvalin, "Development of "oligotyping" for characterization and molecular epidemiology of TEM β-lactamases in members of the family Entero-bacteriaceae", ibid., 34, 2210-2216 (1990).
43. M. Shah, A. Malik, M. Agrawal and S.Singhal, "Phenotypic detection of extended-spectrum and AmpC β-lactamases by a new spot-inoculation method and modified three-dimensional extract test: comparison with the conventional three-dimensional extracttest", J. Antimicrob. Chemother., 54, 684-687 (2004).
44. M. Chayakulkeeree, P. Junsriwong, A. Keerasuntonpong, C. Tribuddharat and V. Thamlikitkul, "Epidemiology of extended-spectrum β-lactamase producing Gramnegative bacilli at Siriraj hospital, Thailand", J. Clin. Microbiol., 36 (6), 1503-1509 (2005).
45. M. H. M. Al-Agamy, M. S-E. M. Ashour and I. Wiegand, "First description of CTX-M β-lactamase-producing clinical E. coli isolates from Egypt", Int. J. Antimicrob. Agents, 27 (6), 545-548 (2006).
46. N. S. Fam, L. Véronique, F. Salwa, A. Laila, M. Estelle, D. Doaa, E. Inas, A. Aisha, K. John and N. Marie-Hélène, "CTX-M-15-producing E. coli clinical isolates in Cairo (Egypt), including isolates of clonal complex ST10 and clones ST131, ST73, and ST405 in both community and hospital settings", Microbial Drug Resistance, 17 (1), 67-73 (2011).
47. H. M. Heffernan, R. E. Woodhouse, C. E. Pope and T. K. Blackmore, "Prevalenceand types of "extended-spectrum β-lactamases among urinary E. coli and Klebsiella spp. in New Zealand", Int. J. Antimicrob. Agents, 34, 544-549 (2009).
48. N. Mendonca, J. Leitao, V. Manageiro, E. Ferreira and M. Canica, "Spread of extended-spectrum β-lactamase CTX-M-producing E. coli clinical isolates in community and nosocomial environments in Portugal", Antimicrob. Agents Chemother., 51 (6), 1946-55 (2007).
49. S. Tofteland, B. Haldorsen, K. H. Dahl, G. S. Simonsen, M. Steinbakk and T. R. Walsh, "Effects of phenotype and genotype on methods for detection of extended spectrum-β-lactamase-producing clinical isolates of E. coli and K. pneumoniae in Norway", J. Clin. Microbiol., 45 (1), 199-205. (2007).